Promontory Therapeutics
Tyler Ames has extensive work experience in research and development. Tyler started their career as a Postdoctoral Researcher at Yale University in 2010 and then moved to UC Berkeley in 2011 for a similar role. In 2012, they joined Promontory Therapeutics and held various positions, including Director of Research, Vice President of Research, and currently, as the Senior Vice President of Research and Development. Tyler'stenure at Promontory Therapeutics has been ongoing since 2012.
Tyler Ames completed their Bachelor of Science (BS) degree in Biology and Biotechnology from Worcester Polytechnic Institute between 2001 and 2003. Following this, they pursued a Doctor of Philosophy (PhD) in Molecular, Cellular, and Developmental Biology at Yale University, from 2004 to 2010.
Promontory Therapeutics
Promontory Therapeutics Inc. is a clinical stage pharmaceutical company developing small molecule immunotherapies. The company's lead candidate, PT-112, is a novel chemical entity under clinical development that exhibits a unique combination of properties, including immunogenic cell death as well as osteotropism that confers advantages indealing with cancers that originate in or metastasize to the bone. Clinical data generated to date across three Phase 1 studies have demonstrated single-agent anti-cancer activity and an attractive tolerability profile, and three Phase 2 studies of PT-112 are underway. The company also sponsors the ongoing clinical study of PT-112 in combination with the PD-L1 inhibitor avelumab under a collaboration agreement with Pfizer and Merck KGaA, Darmstadt, Germany (operating as EMD Serono in the US and Canada), and has an active collaborative research and development agreement (CRADA) with the NCI to conduct a Phase 2 trial utilizing PT-112 in thymic epithelial tumors.